Consequently, the combined immunohistochemical analyses of EGFR, pAkt, NF-κB p65 and/or MIC-1 expression levels with the current histological biomarkers in the patient's prostate biopsies could be helpful in predicting the risk of PC progression to locally invasive and metastatic stages, treatment resistance and biochemical disease recurrence. Here, EGFR is linked to pachyonychia congenita.